Business Wire

Virtuozzo Acquires Jelastic Business to Offer First Full-Stack Cloud Management Solution for Service Providers

5.10.2021 14:00:00 EEST | Business Wire | Press release

Share

Virtuozzo, a high-efficiency virtualization and hyperconverged infrastructure software leader, today announced it has acquired the technology and business of Jelastic, a multi-cloud Platform-as-a-Service (PaaS) software company, following a 10-year partnership.

Bringing Jelastic’s platform and application management capabilities in-house completes Virtuozzo’s core technology stack, delivering a fully integrated solution that supports all relevant anything-as-a-service (XaaS) use cases—from shared hosting to VPS to cloud infrastructure, software-defined storage and application management and modernization.

Virtuozzo offers the first fully integrated, easy-to-use and cost-efficient cloud solution designed for Cloud Service Providers, Managed Service Providers, Hosting Service Providers and their small and medium-sized business (SMB) customers. Virtuozzo also helps service providers increase profitability by providing a comprehensive portfolio of services and management tools.

Many PaaS vendors focus on a single-purpose offering. Jelastic, however, offers a robust, multi-purpose solution that, via the acquisition, will position Virtuozzo as a strong player in the PaaS market and further strengthen Virtuozzo’s position overall in the rapidly growing cloud services space.

“Virtuozzo and Jelastic have been strong partners over the past 10 years because of our complementary technologies and products,” said Alex Fine, CEO of Virtuozzo. “Virtuozzo containers have been incorporated into Jelastic’s Platform-as-a-Service for virtualization since that solution’s inception. Together, our engineering teams have co-developed solutions to enable features required by the market throughout our partnership. And now, with Jelastic joining our team, Virtuozzo can offer a complete, enterprise-grade, turnkey cloud enablement platform with fully integrated orchestration and a single point of management.”

Service Providers Want Simplicity, Automation and Choice

Service providers demand simplification and automation in container and cloud management. Jelastic has been providing a proven production-ready platform to cover these needs for years. The acquisition enables tighter integration and seamless enhancements.

In addition, service providers require a wider set of products to offer to end users. “Freedom of choice” is the core mantra that runs throughout the Jelastic ecosystem. Customers can choose various solutions and services, different types of workloads and management through an automated orchestration.

“Our companies are completely aligned and deeply understand the challenges and opportunities in the service provider industry where Platform-as-a-Service enablement is the key in the process of SaaS-ification and digitalization of its customers,” said Jelastic CEO Ruslan Synytsky. “Our joint partners will benefit from this acquisition since together we become a one-stop shop for Anything-as-a-Service, making it easier to get whatever they need for their users. The joint forces will accelerate the innovation and product development cycles. Together we can raise the bar for the industry standards with the help of our unique technologies that solve real problems of the cloud users.”

Platform-as-a-Service Market Shows Strong Growth

In 2022, the PaaS market is estimated to be worth approximately $71 billion U.S. dollars based on Gartner research. Cloud services (such as PaaS) are anticipated to grow by a high margin at around 27%.

The increased adoption of PaaS among service providers is driven by the end-users’ demand for access to easy-to-manage, high performing and scalable solutions.

By acquiring Jelastic, Virtuozzo can help its service provider partners achieve high ROI by both attracting new end-users and retaining existing customers through enabling XaaS use cases, providing more advanced automation and simplifying their own DevOps processes.

Business as Usual

Business continues as usual, with Jelastic now operating as a division of Virtuozzo—underscoring the value in Jelastic’s brand and technologies. Ruslan Synytsky has been appointed to Chief Technology Officer of Virtuozzo.

Integration of Jelastic’s sales and marketing teams will expand Virtuozzo’s worldwide footprint and brand visibility; and integration of Jelastic’s engineering resources will enable Virtuozzo to accelerate its full stack offering and provide a richer experience across multiple cloud providers.

Terms of the transaction were not disclosed.

About Jelastic

Jelastic is a Multi-Cloud DevOps PaaS for ISVs, telcos, service providers and enterprises needing to speed up development, reduce cost of IT infrastructure, improve uptime and security. The platform automates creation, scaling, clustering and security updates of cloud-native and traditional applications. Jelastic has a unique pay-as-you-use pricing model and is available as public, private, hybrid and multi-cloud in more than 100 data centers worldwide. The platform supports Java, PHP, Ruby, Node.js, Python, .NET, Go environments, as well as Docker and Kubernetes clusters.

About Virtuozzo

Virtuozzo (www.virtuozzo.com) is a leading, global provider of hybrid virtualization, storage, and cloud enablement software solutions. The Company's software-defined, hyperconverged self-service platform and resource management capabilities enable hosting and service providers to provide end-customers with public and private cloud services. Virtuozzo is an industry pioneer who developed the first commercially available container technology 21 years ago. The Company provides software solutions and services to over 750 service providers worldwide. A significant force in the open-source community, Virtuozzo sponsors and/or is a contributor to numerous open-source projects including KVM, Docker, OpenStack, OpenVZ, CRIU, and the Linux kernel.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Heather Ailara / Deb Brown
211 Communications
+1 973-567-6040
heather@211comms.com / deb@211comms.com

Christine Brunelli
Virtuozzo
+1 215-847-7842
christine.brunelli@virtuozzo.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye